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Introduction
Genetically obese rodents that lack leptin (ob/ob mice)
or its receptor (db/db mice) show increased activity of
neuropeptide Y (NPY) circuits in the hypothalamus
due to lack of leptin-induced inhibition of NPY
expression and secretion (1). Such increased hypo-
thalamic NPY signaling contributes to the massive
obesity, hypercorticism, stunted growth, and repro-
ductive defects of these mice (2). Since NPY ablation
in ob/ob mice attenuates all of these defects (3), these
findings demonstrate that NPY is a downstream
mediator of leptin’s central effects.
Recently it was shown that leptin can inhibit bone
synthesis by action within the hypothalamus, and
that mice with no or reduced leptin signaling (ob/ob,
db/db, and transgenic A-ZIP/F-1 fat-deficient mice)
have high bone density associated with increased
bone formation (4). This effect of leptin deficiency
occurred independently of increased body fat or body
weight, and despite the hypercorticism, decreased
somatotropic activity, and hypogonadism in ob/ob
and db/db mice. Intriguingly, central infusion of NPY
for 28 days in wild-type mice had the same inhibito-
ry effect on bone function as leptin had, suggesting
that the increased hypothalamic NPY expression of
leptin-deficient mice does not mediate the associat-
ed increase in bone density (4). However, it is unclear
from this study whether the inhibitory effects on
bone of central NPY infusion are a direct conse-
quence of hypothalamic NPY action or a secondary
effect of the resulting increase in expression (5) and
circulating concentrations (6) of leptin. Furthermore,
NPY mediates its effects through the activation of at
least five different receptors: Y1, Y2, Y4, Y5, and in
the mouse also y6, all of which are expressed in the
hypothalamus (7–9). The potential for simultaneous
activation of all of these receptors by central NPY
infusion makes it difficult to distinguish the true
role of the different types of hypothalamic Y recep-
tors in bone physiology.
NPY synthesis is particularly high in neurons of the
arcuate nucleus, with many of these neurons also
expressing leptin receptors (10). A high percentage of
these arcuate NPY-expressing neurons coexpress the
Y2 receptor (11), which is thought to act as an
autoreceptor that can modulate the expression and
secretion of NPY and other neurotransmitters (12).
Since leptin receptors and Y2 receptors are present on
NPY-expressing neurons of the arcuate nucleus and
are likely to share some common signaling pathways
(1, 10–12), we hypothesized that the Y2 receptor
might be involved in the central regulation of bone
metabolism. To test this hypothesis, we generated
both germline Y2 receptor knockout mice (Y2–/–
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Neuropeptide Y (NPY) is a downstream modulator of leptin action, possibly at the level of the
arcuate nucleus where NPY neurons are known to express both leptin receptors and Y2 receptors.
In addition to the well-described role of NPY and leptin in energy balance and obesity, intracere-
broventricular administration of NPY or leptin also causes bone loss. Here we show that Y2 recep-
tor–deficient mice have a twofold increase in trabecular bone volume as well as greater trabecu-
lar number and thickness compared with control mice. We also demonstrate that central Y2
receptors are crucial for this process, since selective deletion of hypothalamic Y2 receptors in
mature conditional Y2 knockout mice results in an identical increase in trabecular bone volume
within 5 weeks. This hypothalamus-specific Y2 receptor deletion stimulates osteoblast activity
and increases the rate of bone mineralization and formation, with no effect on osteoblast or osteo-
clast surface measurements. The lack of any changes in plasma total calcium, leptinemia, or hypo-
thalamo-pituitary-corticotropic, -thyrotropic, -somatotropic, or -gonadotropic output suggests
that Y2 receptors do not modulate bone formation by humoral mechanisms, and that alteration
of autonomic function through hypothalamic Y2 receptors may play a key role in a major central
regulatory circuit of bone formation.
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mice) and conditional Y2 receptor knockout mice
(Y2lox/lox mice) and investigated the effects of the dele-
tion on bone physiology.
Methods
Generation of germline and conditional Y2 receptor knockout
mice. A targeting vector for the Y2 receptor gene has
been designed that allows the production of both
germline (Y2–/–) and conditional (floxed, Y2lox/lox)
knockout mice. Both of these knockout strategies
result in deletion of the entire coding region of the Y2
receptor, which is encoded by a single exon. Mouse
embryonic stem cells from the strain 129SvJ were
transfected and selected under standard conditions,
and positive embryonic stem cell clones were injected
into blastocysts from C57/BL6 mice. Chimeric off-
spring were crossed with oocyte-specific Cre-recombi-
nase–expressing C57/BL6 mice (13) in order to obtain
either heterozygotes carrying the floxed gene (Y2lox/+
mice) or heterozygotes carrying the Cre-recombinase
gene with the floxed gene already deleted (Y2+/– mice).
Homozygous lines, both Y2–/– and Y2lox/lox, were gener-
ated by crossing the respective heterozygous animals.
All further mice were maintained on this mixed
C57/BL6-129SvJ background.
Adenovirus injection. Y2lox/lox and wild-type Y2+/+ mice,
10–12 weeks old, were anesthetized with 100 mg/kg
ketamine (Pfizer Inc., Sydney, Australia) and 20
mg/kg xylazine (Bayer AG, Leverkusen, Germany)
and injected with adenovirus expressing either
recombinant Cre or green fluorescent protein (GFP)
(The Institute of Physical and Chemical Research,
Riken, Fukyuka, Japan) using a stereotaxic table
(David Kopf Instruments, Tujunga, California, USA).
With the head in the flat-skull position, brain injec-
tion coordinates relative to Bregma were posterior 2.3
mm, lateral ± 0.3 mm, and ventral 5.6 mm, corre-
sponding to the arcuate nucleus (14). One microliter
of either virus (109 plaque-forming units/µl) was
injected bilaterally over a period of 10 minutes using
a 26-gauge guide cannula and a 33-gauge injector
(Plastics One Inc., Roanoke, Virginia, USA) connect-
ed to a Hamilton syringe and a syringe infusion
pump (World Precision Instruments Inc., Sarasota,
Florida, USA). Mice were housed individually for the
ensuing 35 days, with ad libitum access to standard
chow and water.
Tissue collection and analysis. Mice were injected with the
fluorescent tetracycline compounds calcein and deme-
clocycline (15 mg/kg each; Sigma Chemical Co., St.
Louis, Missouri, USA) 10 days and 3 days prior to col-
lection, respectively. At 15–17 weeks of age, germline
and conditional Y2 knockout mice were killed by cervi-
cal dislocation between 1000 and 1400 hours for col-
lection of trunk blood in heparinized tubes, and plasma
was immediately frozen. Both femora were excised and
bisected transversely at the midpoint of the shaft. The
distal halves of the right femora were fixed and embed-
ded, undecalcified, in K-Plast resin (Medim-Medizinis-
che Diagnostik, Giessen, Germany), and 5-µm sagittal
sections were prepared for analysis using BioQuant soft-
ware (R&M Biometrics Inc., Nashville, Tennessee, USA).
Cortical parameters were measured at the bisection
point using the proximal portion of the bone. Cortical
area was calculated by subtraction of the medullary area
from the total bone area, and cortical thickness was cal-
culated by radius difference assuming a perfectly circu-
lar shape. Sections were stained for mineralized bone
(15), and trabecular bone volume, thickness, and num-
ber were calculated (16) in the sample region (see Figure
2). Osteoblast parameters (osteoblast surface, osteoblast
number, and osteoid surface) were estimated using sec-
tions stained with von Kossa stain and toluidine blue.
Only osteoblasts identified adjacent to osteoid surfaces
were included in the analysis. Bone formation (miner-
alizing surface, MS) was estimated using the bone 
surface (BS) coverage of single- and double-labeled 
(sLS and dLS) fluorescent bands using the equation 
MS = {[(0.5 × sLS) + dLS] × 100}/BS, expressed as a per-
centage of BS. Mineral apposition rate (MAR) was esti-
mated by the distance between the labels divided by the
time interval between injection of labels (MAR = inter-
label distance divided by 7, expressed in µm/d). Bone
formation rate (BFR) was calculated after fluorescence
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Figure 1
Effect of germline Y2 receptor deletion on cortical bone of the distal
femur. Cortical area (a) and cortical thickness (b) of the femoral
midshaft of male wild-type mice (WT, white bars) compared with
those of Y2–/– mice (KO, black bars) at 15–17 weeks of age. Values
are mean ± SD of five to eight mice per group.
Figure 2
Sample area for trabecular bone histomorphometry. All trabecular
bone bordered distally by the epiphyseal growth plate and extending
4.5 mm proximally was sampled.
microscopy (Leica Microsystems, Heerbrugg, Switzer-
land) as BFR = MS/BS × MAR, expressed in µm2/µm/d)
(17). For measurements of osteoclast surface and osteo-
clast number, sections were stained for tartrate-resist-
ant acid phosphatase (TRAP) activity as described pre-
viously (18), with only multinucleated, TRAP-positive
cells included in the analysis. Radioimmunoassay kits
were used to determine plasma concentrations of leptin
(Linco Research Inc., St. Louis, Missouri, USA), corti-
costerone, free T4, testosterone (ICN Biomedicals Inc.,
Costa Mesa, California, USA), and IGF-1 (Bioclone Aus-
tralia Pty. Ltd., Marrickville, Australia). Plasma total cal-
cium levels were determined using a colorimetric assay
kit from Sigma Chemical Co.
In situ PCR. Fresh-frozen coronal brain sections were
fixed in 4% paraformaldehyde in PBS for 30 minutes,
washed once (for 5 minutes) in PBS, and treated with
proteinase K (5 µg/ml) for 1 minute at room tempera-
ture. Sections were then rinsed for 5 minutes in PBS
followed by a 5-minute wash in 100% ethanol. After
drying the slides, Gene Frames (Advanced Biotech-
nologies Ltd., Epsom, United Kingdom) were put
around each section. One hundred microliters of PCR
mix containing digoxigenin-labeled nucleotides and a
combination of primers was prepared: oligo C (5′-
TTAACATCAGCTGGCCTAGC-3′) and oligo D (5′-
GGAAGTCACCAACTAGAATGG-3′) were used to verify
the Y2lox/lox genotype; oligo C and oligo E (5′-
AGCATCCAGAGAAGTGCAAC-3′) were used to verify the
deleted Y2–/– genotype. Each primer mixture was pre-
heated to 65°C, then added to the sections, which were
then sealed off with a self-adhesive plastic cover slip.
In situ PCR was carried out using an OmniSlide ther-
mal cycler (Hybaid Ltd., Teddington, Middlesex, Unit-
ed Kingdom), with pretreatment at 95°C for 5 min-
utes followed by 40 cycles of denaturing at 95°C for 1
minute, annealing at 61°C for 1 minute, and extension
at 72°C for 25 seconds. At the end of PCR, the cover
slips and Gene Frames were removed and slides were
washed for 5 minutes in xylene followed by 5 minutes
in 100% ethanol. Staining to detect the incorporated
label was performed as described earlier (8).
Statistical analyses. All data were assessed by factorial
ANOVA followed by the Fisher or contrast post-hoc
tests, using StatView version 4.5 or Super-ANOVA
(Abacus Concepts Inc., San Francisco, California, USA).
For all statistical analyses, P < 0.05 was accepted as
being statistically significant.
Results
Effects of germline Y2 receptor deletion on bone formation.
Skeletal phenotypes of Y2–/– mice were analyzed in
the femora, and cortical bone parameters were
assessed at the midshaft dissection point. There was
no significant difference in the cross-sectional area
or the thickness of the cortical bone between wild-
type and germline Y2–/– mice, although a trend
toward increased cortical bone in the knockout ani-
mals can be seen (Figure 1). However, trabecular bone
volume of the distal femoral metaphysis (sample
region shown in Figure 2) was increased twofold in
germline Y2–/– mice compared with wild-type ani-
mals, with heterozygous mice showing a tendency
toward increased trabecular bone volume (Figure 3a).
This increased trabecular volume of Y2–/– animals
was associated with a significant increase in the num-
ber and thickness of trabecular structures (Figure 3,
b and c, and Figure 4).
Y2 receptor mRNA has been found in a variety of
central and peripheral tissues (8, 19, 20). In order to
determine whether bone tissue expresses Y receptors
through which NPY could directly regulate bone
function, we used RT-PCR to investigate the existence
of mRNA for all of the five known Y receptors in total
bone tissue of wild-type mice or the osteoblast cell
line MC3T3 E1. Primers that are specific for each of
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Figure 3
Effect of germline Y2 receptor deletion on tra-
becular bone of the distal femoral metaphysis.
Trabecular bone volume (a), trabecular number
(b), and trabecular thickness (c) of femora from
male wild-type mice (WT, white bars) compared
with heterozygous Y2+/– (het, gray bars) and
homozygous Y2–/– mice (KO, black bars) at
15–17 weeks of age. Values are mean ± SD of five
to eight mice per group. *P < 0.05, **P < 0.01
versus wild-type mice.
Figure 4
Sagittal micrographs of the distal femoral metaphysis of germline Y2–/–
male mice at 15–17 weeks of age compared with Y2+/– and wild-type
(Y2+/+) control male mice. Figures show darkly stained bone tissue and
are representative of the respective groups. Bar represents 1 mm.
the receptor genes and are located on two different
exons were used to ensure that only properly spliced
mRNA and not genomic DNA contaminants were
amplified. RT-PCR did not yield products specific for
any of the Y receptors in any of these preparations,
suggesting that NPY and Y2 receptor deletion influ-
ences bone density by receptors in locations other
than in bone itself.
Effects of hypothalamus-specific Y2 receptor deletion on
bone formation. A possible central role of Y2 receptors
in bone physiology was investigated after selective
removal of hypothalamic Y2 receptors in conditional
Y2 receptor knockout mice. Ten- to twelve-week old
Y2lox/lox and Y2+/+ mice were bilaterally injected into the
hypothalamus with adenovirus expressing either Cre-
recombinase or GFP, and femurs of these mice were
collected 35 days later when mice were 15–17 weeks of
age. In these experiments, the two groups of control
mice (GFP-injected Y2lox/lox and Cre-injected Y2+/+
mice) were indistinguishable from each other for all
parameters investigated, and data were therefore
pooled into a single control group for all figures.
Appropriate positioning of the stereotaxic injection
coordinates was monitored by the appearance of
green fluorescence in the hypothalamus of GFP-
injected animals (Figure 5a). Cre gene expression and
consequent Y2 receptor gene deletion in the hypo-
thalamus were confirmed at 35 days after adenovirus
injection by in situ PCR analysis of coronal brain sec-
tions isolated from these animals (Figure 5, b–f).
The selective deletion of hypothalamic Y2 receptors
in adult mice resulted in a bone phenotype identical to
that seen in germline Y2–/– animals. A twofold increase
in trabecular bone volume was produced during the 
5-week period of hypothalamic Y2 receptor deficiency
(Figure 6a and Figure 7). Consistent with germline Y2
receptor knockout, hypothalamic Y2 deletion resulted
in increased trabecular number and trabecular thick-
ness (Figure 6, b and c). There was no indication of
change in resorption as measured by osteoclast surface
(Figure 8a), but osteoclast number was significantly
reduced (Figure 8b). Osteoblast surface, osteoblast
number, osteoid surface, and mineralizing surface were
all unaffected by hypothalamic Y2 receptor deletion
(Figure 8, c–f). However, the rates of bone mineral
apposition and bone formation were significantly
increased by the hypothalamic Y2 receptor deletion
(Figure 8, g and h). This measure of the speed of bone
mineralization, as indicated by the distance between
the two fluorescent bands, showed that hypothalamus-
specific Y2 receptor knockout animals laid down sub-
stantially more bone than did control animals (Figure
9). Indeed, bone mineral apposition rate and the asso-
ciated bone formation rate in the conditional knock-
outs were both around twofold higher than these rates
in controls (Figure 8, g and h).
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Figure 5
Expression of GFP and in situ PCR of the hypothalamus of Cre-ade-
novirus–injected Y2lox/lox mice and germline Y2–/– mice. (a) Fluores-
cence micrograph of the hypothalamus of a Y2lox/lox animal 21 days
after injection of GFP-expressing adenovirus. Bar represents 2 mm.
(b) Schematic drawing of the position of the primers (oligo C, D, and
E) used for in situ PCR. (c) In situ PCR on a brain section from a
Y2lox/lox animal using oligo C and oligo D. (d) In situ PCR on a brain
section from a Y2–/– animal using oligo C and oligo D. (e) In situ PCR
on a brain section from a Cre-adenovirus–injected Y2lox/lox animal
using oligo C and oligo E. (f) In situ PCR on a brain section from a
Cre-adenovirus–injected Y2lox/lox animal using oligo C and oligo E
without enzyme. Bar represents 1 mm in c–f.
Figure 6
Effect of adult induced hypothalamus-specific Y2
receptor deletion on trabecular bone of the distal
femoral metaphysis. Trabecular bone volume (a),
trabecular number (b), and trabecular thickness (c)
in male Y2+/+ Cre-adeno-virus–injected or Y2lox/lox
GFP-adenovirus–injected control mice (white bars)
compared with Y2lox/lox Cre-adenovirus–injected
mice (KO, black bars) at 15–17 weeks of age. Val-
ues are mean ± SD of five to seven mice per group.
*P < 0.01, **P < 0.001 versus controls.
Plasma concentrations of total calcium, leptin, free
T4, IGF-1, and testosterone were unaffected by
germline or conditional Y2 receptor knockout (Table
1). There was no significant effect of germline Y2 recep-
tor knockout on corticosteronemia, but conditional Y2
receptor knockout mice had significantly greater cor-
ticosteronemia than did control mice injected with
GFP- or Cre-expressing adenovirus (Table 1).
Discussion
Here we provide the first evidence that hypothalamic
Y2 receptors are involved in a tonic inhibition of bone
formation. The absence of detectable levels of Y recep-
tor mRNAs in bone tissue is further evidence that this
effect of Y2 deficiency occurs by a central mechanism.
It is noteworthy that the bone phenotype of condi-
tional hypothalamic Y2 receptor knockout mice
shown here is similar to that reported for mice defi-
cient in leptin action (4). Trabecular bone density and
the rate of bone mineralization and formation are
increased in Y2 knockout mice, with no increase in
osteoblast or osteoid surface, or osteoblast number.
Thus deletion of hypothalamic Y2 receptors acts to
release a tonic inhibition of the activity of trabecular
osteoblast activity, increasing the rate of bone miner-
alization and formation twofold. In contrast with the
ob/ob and db/db mice, in which osteoclast number was
increased, osteoclast number in hypothalamic Y2
receptor knockout mice was reduced, suggesting dif-
ferent osteoclast regulation between the two models.
However, osteoclast surface was not affected by Y2
deletion, suggesting an increase in osteoclast size in
these knockouts. Such a change in osteoclast mor-
phology is consistent with an increase in resorptive
activity per cell (21, 22).
Both Y2 and leptin receptors are found on NPY-
expressing neurons in the arcuate nucleus (10, 11).
Deficiency of either the leptin receptor (1) or the Y2
receptor leads to increased NPY expression in the arcu-
ate nucleus (data not shown), consistent with both
receptors regulating bone formation by a common
pathway. In support of this, the high-bone-density phe-
notype of Y2–/– mice and ob/ob mice was not increased
in Y2–/–, ob/ob double knockout mice (unpublished
observations from our group), indicating lack of addi-
tive, independent effects of the two gene deficiencies. 
It is not clear whether the high hypothalamic NPY 
The Journal of Clinical Investigation | April 2002 | Volume 109 | Number 7 919
Figure 7
Sagittal micrographs of the distal femoral metaphysis of control and
hypothalamus-specific Y2 receptor knockout mice: Cre-
adenovirus–injected wild-type control (Cre-Y2+/+), Y2lox/lox control, GFP-
injected control (GFP-Y2lox/lox), and Cre-injected hypothalamic Y2
receptor knockout (Cre-Y2lox/lox). All mice were males, 15–17 weeks of
age. Measurements were taken 5 weeks after hypothalamic injection.
Each micrograph is a representative sample. Bar represents 1 mm.
Figure 8
Effect of hypothalamus-specific Y2 receptor deletion on trabecular bone cell activity in the distal femoral metaphysis. Osteoclast surface (a),
osteoclast number (b), osteoblast surface (c), osteoblast number (d), osteoid surface (e), mineralizing surface (f), mineral apposition rate
(g), and bone formation rate (h) of femurs from male Y2+/+ Cre-adenovirus–injected or Y2lox/lox GFP- adenovirus–injected control mice (white
bars) compared with Y2lox/lox Cre-adenovirus–injected knockouts (KO, black bars) at 15–17 weeks of age. Values are mean ± SD of five to
seven mice per group. *P < 0.05 versus controls.
expression common to mice deficient in leptin action
or Y2 receptors is causally related to the high bone den-
sity, because 28-day intracerebroventricular NPY infu-
sion actually decreased bone density (though it proba-
bly also resulted in hyperleptinemia) (4). It is note-
worthy that germline Y4 receptor knockout mice gen-
erated in our laboratory using the same strategies used
for the Y2 receptor knockout, and maintained on the
same background, do not present an increased bone
forming phenotype. These data collectively suggest
that Y2 receptor signaling specifically is important in
regulating bone mass.
NPY in the hypothalamus influences peripheral tis-
sues by neuroendocrine effects. Central NPY activates
the hypothalamo-pituitary-corticotropic axis (23, 24)
while inhibiting activity of
the -thyrotropic (24, 25), 
-somatotropic (24, 26), and 
-gonadotropic axes (24, 26,
27). It is likely that these
effects are mediated by NPY
projections to neurons that
secrete releasing hormones
into the pituitary portal sys-
tem (24). This mechanism
explains why deficiency of
leptin action and the subse-
quently increased central
NPY expression and secretion
tonus not only contributes to
massive obesity, but also
leads to neuroendocrinologi-
cal perturbations that would
be expected to decrease bone mass, namely hypercor-
ticism, hypothyroid-ism (28–30), reduced soma-
totropic activity, and hypogonadism (2, 4). In con-
trast, germline or hypothalamus-specific Y2 receptor
deletion did not induce any obvious endocrine imbal-
ances that would have impacts on bone homeostasis.
Knockout animals showed no significant change
from controls in plasma concentrations of total calci-
um, leptin, free T4, IGF-1, or testosterone, and fertil-
ity was not impaired. The divergent changes in corti-
costeronemia seen in germline and conditional Y2
receptor knockout mice are not likely to explain the
increased bone mass phenotype observed in both
knockout models. These findings suggest that Y2
receptor deficiency does not influence bone forma-
tion via modulation of humoral factors.
Another mechanism by which central NPY can
influence peripheral tissues is by alterations in auto-
nomic neuronal activity. This is probably mediated
by NPY projections from the hypothalamus to brain
stem areas where sympathetic or parasympathetic
neuronal activity is modulated (31). Whereas central
Y1 and Y5 receptors are the most likely mediators of
the strong stimulatory effect of NPY on food intake,
Y2 receptors are known to be involved in the regula-
tion of autonomic processes, such as central regula-
tion of pancreatic secretion, gut motility (32, 33), and
cardiovascular function (34). Notably, autonomic
function is also disturbed in genetically obese
rodents lacking leptin function (35, 36). Since rat
bone tissue has recently been shown to contain auto-
nomic fibers (37, 38), it is possible that alteration of
autonomic activity in the bone presents a novel
mechanism by which central regulators of bone
homeostasis mediate their effects.
These data clearly indicate a major role of hypo-
thalamic Y2 receptors in the regulation of bone mass.
The rapid increase in bone volume in adult mice after
central deletion of Y2 receptor suggests new possi-
bilities for the prevention and anabolic treatment 
of osteoporosis.
920 The Journal of Clinical Investigation | April 2002 | Volume 109 | Number 7
Figure 9
Effect of hypothalamus-specific Y2 receptor deletion on bone min-
eralization in the distal femoral metaphysis. Fluorescence micro-
graphs of male GFP-adenovirus–injected Y2lox/lox control animals com-
pared with Cre-adenovirus–injected Y2lox/lox knockout mice at 15–17
weeks of age, showing the greater distance between the bands in
knockout mice. Bar represents 1 mm.
Table 1
Plasma total calcium, leptin, corticosterone (Cortico), free T4, IGF-1, and testosterone (Testost)
concentrations
Y2+/+ Y2+/– Y2–/– GFP-Y2lox/lox Cre-Y2+/+ Cre-Y2lox/lox
Calcium (mg/dl) 10.1 ± 0.5 10.0 ± 0.4 10.0 ± 0.5 10.4 ± 1.6 8.5 ± 0.8 9.0 ± 0.4
(21) (15) (21) (5) (3) (11)
Leptin (ng/ml) 6.6 ± 2.4 7.2 ± 2.8 6.2 ± 1.6 4.6 ± 0.4 ND 4.4 ± 0.7
(6) (6) (6) (4) (5)
Cortico (ng/ml) 102 ± 32 48 ± 14 64 ± 17 54 ± 23 73 ± 38 139 ± 18A
(10) (19) (18) (5) (3) (11)
Free T4 (pmol/l) 20.7 ± 4.0 16.4 ± 2.9 20.2 ± 3.6 19.2 ± 1.1 16.3 23.3 ± 1.6
(4) (11) (8) (3) (1) (5)
IGF-1 (ng/ml) 262 ± 29 ND 235 ± 26 320 ± 58 182 ± 26 238 ± 36
(20) (17) (5) (3) (11)
Testost (nmol/l) 7.6 ± 2.4 5.1 ± 2.5 5.9 ± 2.7 ND ND ND
(5) (10) (9)
Data are presented as mean ± SEM, with sample size indicated in parentheses. AP < 0.05 versus GFP-aden-
ovirus– or CRE-adenovirus–injected controls. ND, not determined.
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